Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Neoplasms, Connective Tissue

ClinicalTrials.gov lists 1,727 trials for Neoplasms, Connective Tissue or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 137.

MeSH D009372 Neoplasms Neoplasm C04 C17
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 291 Phase 1/2 Phase 1/2 135 Phase 2 Phase 2 511 Phase 2/3 Phase 2/3 21 Phase 3 Phase 3 136 Phase 4 Phase 4 38 Not applicable Not applicable 211 Observational Observational 361 Phase 1 Phase 1 291 Phase 1/2 Phase 1/2 135 Phase 2 Phase 2 511 Phase 2/3 Phase 2/3 21 Phase 3 Phase 3 136 Phase 4 Phase 4 38 Not applicable Not applicable 211 Observational Observational 361

Trials per phase (log scale)

2 more sections with rows

6 of the 1,727 trials are tagged with Neoplasms, Connective Tissue itself; the rest are tagged with a narrower condition beneath it.

Get the Neoplasms, Connective Tissue report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Neoplasms, Connective Tissue trials start? (37)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 9 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Unknown)

Top of scale: 98

1990: 1 trials (Phase 2 1) 1991: 1 trials (Phase 2 1) 1992: 3 trials (Observational 2, Phase 2 1) 1993: 2 trials (Observational 1, Phase 2 1) 1994: 4 trials (Phase 3 2, Phase 2 1, Phase 1 1) 1995: 5 trials (Observational 1, Phase 3 2, Phase 2 1, Phase 1 1) 1996: 10 trials (Observational 1, Phase 3 3, Phase 2 5, Phase 1 1) 1997: 12 trials (Observational 2, Not applicable 1, Phase 3 1, Phase 2 5, Phase 1 3) 1998: 18 trials (Observational 6, Phase 3 3, Phase 2 5, Phase 1/2 1, Phase 1 3) 1999: 18 trials (Observational 2, Phase 2 10, Phase 1/2 2, Phase 1 4) 2000: 28 trials (Observational 6, Phase 3 1, Phase 2 8, Phase 1/2 4, Phase 1 9) 2001: 27 trials (Observational 3, Not applicable 1, Phase 3 1, Phase 2 12, Phase 1/2 1, Phase 1 9) 2002: 22 trials (Observational 7, Phase 3 1, Phase 2 11, Phase 1/2 1, Phase 1 2) 2003: 22 trials (Observational 2, Not applicable 2, Phase 3 5, Phase 2 10, Phase 1 3) 2004: 36 trials (Observational 3, Not applicable 1, Phase 4 1, Phase 3 4, Phase 2 15, Phase 1/2 4, Phase 1 8) 2005: 44 trials (Observational 5, Not applicable 2, Phase 4 1, Phase 3 3, Phase 2 21, Phase 1/2 3, Phase 1 9) 2006: 35 trials (Observational 2, Not applicable 2, Phase 3 5, Phase 2/3 1, Phase 2 17, Phase 1/2 1, Phase 1 7) 2007: 57 trials (Other 1, Observational 12, Not applicable 2, Phase 3 8, Phase 2/3 1, Phase 2 20, Phase 1/2 2, Phase 1 11) 2008: 57 trials (Observational 17, Not applicable 2, Phase 4 4, Phase 3 5, Phase 2/3 1, Phase 2 21, Phase 1/2 2, Phase 1 5) 2009: 46 trials (Observational 7, Not applicable 4, Phase 3 8, Phase 2 18, Phase 1/2 3, Phase 1 6) 2010: 58 trials (Observational 16, Not applicable 1, Phase 4 3, Phase 3 10, Phase 2/3 2, Phase 2 14, Phase 1/2 3, Phase 1 9) 2011: 59 trials (Observational 7, Not applicable 12, Phase 4 3, Phase 3 5, Phase 2/3 2, Phase 2 18, Phase 1/2 2, Phase 1 10) 2012: 55 trials (Observational 6, Not applicable 10, Phase 4 3, Phase 3 7, Phase 2/3 2, Phase 2 18, Phase 1/2 2, Phase 1 7) 2013: 51 trials (Observational 11, Not applicable 6, Phase 4 4, Phase 3 4, Phase 2 13, Phase 1/2 6, Phase 1 7) 2014: 73 trials (Observational 19, Not applicable 13, Phase 4 1, Phase 3 3, Phase 2/3 2, Phase 2 20, Phase 1/2 4, Phase 1 11) 2015: 67 trials (Observational 15, Not applicable 12, Phase 4 1, Phase 3 3, Phase 2 18, Phase 1/2 8, Phase 1 10) 2016: 60 trials (Observational 11, Not applicable 8, Phase 4 2, Phase 3 3, Phase 2/3 2, Phase 2 14, Phase 1/2 5, Phase 1 15) 2017: 71 trials (Observational 12, Not applicable 6, Phase 4 2, Phase 3 4, Phase 2 31, Phase 1/2 8, Phase 1 8) 2018: 87 trials (Observational 18, Not applicable 13, Phase 3 11, Phase 2 21, Phase 1/2 9, Phase 1 15) 2019: 72 trials (Observational 16, Not applicable 10, Phase 3 4, Phase 2 21, Phase 1/2 7, Phase 1 14) 2020: 91 trials (Observational 21, Not applicable 19, Phase 4 3, Phase 3 5, Phase 2 18, Phase 1/2 5, Phase 1 20) 2021: 96 trials (Observational 19, Not applicable 16, Phase 4 3, Phase 3 3, Phase 2/3 3, Phase 2 27, Phase 1/2 11, Phase 1 14) 2022: 68 trials (Observational 23, Not applicable 10, Phase 3 3, Phase 2/3 1, Phase 2 13, Phase 1/2 6, Phase 1 12) 2023: 72 trials (Observational 13, Not applicable 9, Phase 4 3, Phase 3 7, Phase 2/3 2, Phase 2 16, Phase 1/2 9, Phase 1 13) 2024: 98 trials (Observational 27, Not applicable 17, Phase 4 1, Phase 3 4, Phase 2 25, Phase 1/2 10, Phase 1 14) 2025: 77 trials (Observational 32, Not applicable 16, Phase 4 1, Phase 3 3, Phase 2/3 1, Phase 2 10, Phase 1/2 4, Phase 1 10)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 84
2025 77
2024 98
2023 72
2022 68
2021 96
2020 91
2019 72
2018 87
2017 71

Showing 10 of 37 earlier years.

Start your 14-day trial Email me all 37 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 100 trials starting in 2026 and about 88 in 2027, the average of the 24 months through September, counted as registered and carried forward, with about 0.7 times the starts already registered for the rest of 2026 added. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 15 percent and ran about 1 percent high against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. The part-way figures are from forecasts that used a multiple fitted only on earlier years. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 197 trials still running at the 2026-10-09 snapshot; registered median of 39 months across 1,014 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Neoplasms, Connective Tissue trials in? (10)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 291
Phase 1/2 135
Phase 2 511
Phase 2/3 21
Phase 3 136
Phase 4 38
Not applicable 211
Observational 361
Expanded access 22
Unknown 1

How many Neoplasms, Connective Tissue trials are recruiting? (13)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 59
Recruiting 280
Enrolling by invitation 7
Active, not recruiting 113
Available 8

Showing 5 of 13 statuses.

Start your 14-day trial Email me all 13 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Neoplasms, Connective Tissue trials? (7)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Cancer Institute (NCI) 137
Children's Oncology Group 41
Novartis Pharmaceuticals 33
European Organisation for Research and Treatment of Cancer - EORTC 24
Gynecologic Oncology Group 20

Showing 5 of 7 sponsors.

Start your 14-day trial Email me all 7 sponsors as a PDF

Which drugs are being tested for Neoplasms, Connective Tissue? (4)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Imatinib 74
Cytoxan 53
(nab)-paclitaxel 30
Irinotecan 24

Interventions as named in the registry (11)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Doxorubicine 56
Ifosfamid 46
Cisplatin 1 36
or carboplatin 34
Etoposid 30

Showing 5 of 11 interventions.

Start your 14-day trial Email me all 11 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Neoplasms, Connective Tissue trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Vomiting 387 107
Abdominal pain 373 97
Febrile neutropenia 306 61
Dehydration 274 92
Nausea 267 91

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Neoplasms, Connective Tissue? (12)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
ETIOSARC study : environmental aetiology of sarcomas from a French prospective multicentric population-based case-control study-study protocol. BMJ open 2019 Yes
Tumour-induced osteomalacia. Nature reviews. Disease primers 2017 Yes
Rare missense variants in POT1 predispose to familial cutaneous malignant melanoma. Nature genetics 2014 Yes
Mechanisms of sarcoma development. Nature reviews. Cancer 2003 Yes
Gastrointestinal stromal tumours (GIST): biology and treatment. Annals of oncology : official journal of the European Society for Medical Oncology 2002 Yes

Showing 5 of 12 publications.

Start your 14-day trial Email me all 12 publications as a PDF

Sub-conditions in MeSH (15)

MeSH descendants one level down with at least one trial, most trials first.

+5 more sub-conditions

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages